Cyclophilin A (CypA) is overexpressed in a number of human cancer types, but the mechanisms by which the protein promotes oncogenic properties of cells are not understood. Here we demonstrate that CypA binds the CrkII adaptor protein and prevents it from switching to the inhibited state. CrkII influences cell motility and invasion by mediating signaling through its SH2 and SH3 domains. CrkII Tyr221 phosphorylation by the Abl or EGFR kinases induces an inhibited state of CrkII by means of an intramolecular SH2-pTyr221 interaction, causing signaling interruption. We show that the CrkII phosphorylation site constitutes a binding site for CypA. Recruitment of CypA sterically restricts the accessibility of Tyr221 to kinases, thereby suppressing CrkII phosphorylation and promoting the active state. Structural, biophysical and in vivo data show that CypA augments CrkII-mediated signaling. A strong stimulation of cell migration is observed in cancer cells wherein both CypA and CrkII are greatly upregulated.
At a glance
- Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology 72, 399–404 (1991). et al.
- Cyclophilin A: a key player for human disease. Cell Death Dis. 4, e888 (2013). , &
- Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c. Biochem. Biophys. Res. Commun. 393, 325–330 (2010). et al.
- Catalysis of cis/trans isomerization in native HIV-1 capsid by human cyclophilin A. Proc. Natl. Acad. Sci. USA 99, 5247–5252 (2002). , , , &
- Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A. Proc. Natl. Acad. Sci. USA 99, 1899–1904 (2002). , , &
- Structural insights into the catalytic mechanism of cyclophilin A. Nat. Struct. Biol. 10, 475–481 (2003). , , , &
- Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell. Mol. Life Sci. 55, 423–436 (1999). &
- The mode of action of peptidyl prolyl cis/trans isomerases in vivo: binding vs. catalysis. FEBS Lett. 426, 17–20 (1998). , &
- An overview of cyclophilins in human cancers. J. Int. Med. Res. 38, 1561–1574 (2010). &
- Proteomics identification of cyclophilin a as a potential prognostic factor and therapeutic target in endometrial carcinoma. Mol. Cell. Proteomics 7, 1810–1823 (2008). et al.
- Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. Cancer Res. 65, 8853–8860 (2005). et al.
- Cyclophilin A enhances cell proliferation and tumor growth of liver fluke–associated cholangiocarcinoma. Mol. Cancer 10, 102 (2011). et al.
- Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346, 796–798 (1995). , , , &
- Crk and CrkL adaptor proteins: networks for physiological and pathological signaling. Cell Commun. Signal. 7, 13 (2009). , , &
- Involvement of adaptor protein Crk in malignant feature of human ovarian cancer cell line MCAS. Oncogene 25, 3547–3556 (2006). et al.
- Molecular and immunohistochemical analysis of signaling adaptor protein Crk in human cancers. Cancer Lett. 180, 55–61 (2002). et al.
- Increased C-CRK proto-oncogene expression is associated with an aggressive phenotype in lung adenocarcinomas. Oncogene 22, 7950–7957 (2003). et al.
- Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol. Cancer Res. 7, 1582–1592 (2009). et al.
- CrkI adapter protein modulates cell migration and invasion in glioblastoma. Cancer Res. 63, 2335–2337 (2003). et al.
- Crk at the quarter century mark: perspectives in signaling and cancer. J. Cell. Biochem. 115, 819–825 (2014). , , &
- Crk adaptor proteins act as key signaling integrators for breast tumorigenesis. Breast Cancer Res. 14, R74 (2012). et al.
- Crk family adaptor proteins trans-activate c-Abl kinase. Genes Cells 6, 431–440 (2001). et al.
- Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol. Cell 100, 617–631 (2008). , &
- The mammalian-membrane two-hybrid assay (MaMTH) for probing membrane-protein interactions in human cells. Nat. Methods 11, 585–592 (2014). et al.
- Proline cis-trans isomerization controls autoinhibition of a signaling protein. Mol. Cell 25, 413–426 (2007). , , , &
- Structural basis for regulation of the Crk signaling protein by a proline switch. Nat. Chem. Biol. 7, 51–57 (2011). , , , &
- Structural basis for the transforming activity of human cancer-related signaling adaptor protein CRK. Nat. Struct. Mol. Biol. 14, 503–510 (2007). et al.
- Molecular determinants of a regulatory prolyl isomerization in the signal adapter protein c-CrkII. ACS Chem. Biol. 9, 1145–1152 (2014). &
- c-Abl kinase regulates the protein binding activity of c-Crk. EMBO J. 13, 2341–2351 (1994). , &
- Phosphorylation of CrkII adaptor protein at tyrosine 221 by epidermal growth factor receptor. J. Biol. Chem. 273, 17186–17191 (1998). et al.
- Direct demonstration of an intramolecular SH2-phosphotyrosine interaction in the Crk protein. Nature 374, 477–479 (1995). et al.
- Regulation of integrin-mediated cellular responses through assembly of a CAS/Crk scaffold. Biochim. Biophys. Acta 1692, 63–76 (2004). &
- Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J. Biol. Chem. 280, 23668–23674 (2005). et al.
- Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226, 544–547 (1984). , , , &
- Genetically encoded fluorescent reporters of protein tyrosine kinase activities in living cells. Proc. Natl. Acad. Sci. USA 98, 15003–15008 (2001). , , &
- MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem. Biophys. Res. Commun. 128, 898–905 (1985). , , &
- Phosphorylation of c-Crk II on the negative regulatory Tyr222 mediates nerve growth factor–induced cell spreading and morphogenesis. J. Biol. Chem. 275, 24787–24797 (2000). et al.
- Overexpression of CRKII increases migration and invasive potential in oral squamous cell carcinoma. Cancer Lett. 303, 84–91 (2011). et al.
- The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway. Nat. Cell Biol. 8, 815–825 (2006). , , &
- Tyrosine phosphorylation of the CrkII adaptor protein modulates cell migration. J. Cell Sci. 116, 3145–3155 (2003). et al.
- Impedance measurement for real time detection of neuronal cell death. J. Neurosci. Methods 203, 69–77 (2012). et al.
- Paxillin comes of age. J. Cell Sci. 121, 2435–2444 (2008). &
- FAK and paxillin dynamics at focal adhesions in the protrusions of migrating cells. Sci. Rep. 4, 6024 (2014). et al.
- Tyrosine 207 in CRKL is the BCR/ABL phosphorylation site. Oncogene 14, 507–513 (1997). , , &
- BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl. Oncogene 21, 3225–3231 (2002). et al.
- Domain organization differences explain Bcr-Abl's preference for CrkL over CrkII. Nat. Chem. Biol. 8, 590–596 (2012). et al.
- Models of Crk adaptor proteins in cancer. Genes Cancer 3, 341–352 (2012). &
- Directed cell invasion and migration during metastasis. Curr. Opin. Cell Biol. 24, 277–283 (2012). , &
- CAS/Crk coupling serves as a 'molecular switch' for induction of cell migration. J. Cell Biol. 140, 961–972 (1998). et al.
- Immunophilins control T lymphocyte adhesion and migration by regulating CrkII binding to C3G. J. Immunol. 193, 3966–3977 (2014). , , &
- Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain. Oncogene 24, 8187–8199 (2005). et al.
- Phosphorylation of Crk on tyrosine 251 in the RT loop of the SH3C domain promotes Abl kinase transactivation. Oncogene 30, 4645–4655 (2011). et al.
- NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995). et al.
- Automated NMR structure calculation with CYANA. Methods Mol. Biol. 278, 353–378 (2004).
- Protein backbone and side chain torsion angles predicted from NMR chemical shifts using artificial neural networks. J. Biomol. NMR 56, 227–241 (2013). &
- The HADDOCK web server for data-driven biomolecular docking. Nat. Protoc. 5, 883–897 (2010). , &
- Supplementary Text and Figures (7,609 KB)
Supplementary Results, Supplementary Figures 1–13 and Supplementary Table 1.